Great preliminary results across all cohorts, especially considering each cohort were on ascending doses to the last.
They only need an ORR of >5/26 to pass Ph2a, so these preliminary results are indicative of a strong chance of achieving that and more !
Holding......hope for cancer patients!
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer, page-2
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.8¢ |
Change
-0.012(12.0%) |
Mkt cap ! $24.13M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.5¢ | 8.6¢ | $614.5K | 5.826M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 122997 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.4¢ | 11000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| ATX (ASX) Chart |